VMP-like sequences of pathogenic borrelia species and strains
View Patent ↗The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia , the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino acid sequences, application of the DNA and amino acid sequences to the production of polypeptides as antigens for immunoprophylaxis, immunotherapy, and immunodiagnosis. Also disclosed are the use of the nucleic acid sequences as probes or primers for the detection of organisms causing Lyme disease, relapsing fever, or related disorders, and kits designed to facilitate methods of using the described polypeptides, DNA segments and antibodies.
1. A recombinant nucleic acid comprising a nucleotide sequence that encodes at least 12 contiguous amino acids of SEQ ID NO:59 operably linked to a heterologous promoter.
2. The recombinant nucleic acid of claim 1 , wherein the nucleotide sequence encodes at least 35 contiguous amino acids of SEQ ID NO:59.
3. The recombinant nucleic acid of claim 1 , wherein the nucleotide sequence encodes at least 50 contiguous amino acids of SEQ ID NO:59.
4. The recombinant nucleic acid of claim 1 , wherein the nucleotide sequence encodes a peptide comprising SEQ ID NO:59.
5. The recombinant nucleic acid of claim 1 , wherein the nucleic acid comprises at least 50 contiguous nucleotides of SEQ ID NO:58.
6. The recombinant nucleic acid of claim 1 , wherein the nucleic acid comprises at least 110 contiguous nucleotides of SEQ ID NO:58.
7. The recombinant nucleic acid of claim 1 , wherein the nucleic acid comprises the nucleotide sequence of SEQ ID NO:58.
8. A recombinant nucleic acid comprising a nucleotide sequence that encodes at least 12 contiguous amino acids of SEQ ID NO:34 operably linked to a heterologous promoter.
9. The recombinant nucleic acid of claim 8 , wherein the nucleotide sequence encodes at least 35 contiguous amino acids of SEQ ID NO:34.
10. The recombinant nucleic acid of claim 8 , wherein the nucleotide sequence encodes at least 50 contiguous amino acids of SEQ ID NO:34.
11. The recombinant nucleic acid of claim 8 , wherein the nucleotide sequence encodes a peptide comprising SEQ ID NO:34.
12. The recombinant nucleic acid of claim 8 , wherein the nucleic acid comprises at least 50 contiguous nucleotides of SEQ ID NO:33.
13. The recombinant nucleic acid of claim 8 , wherein the nucleic acid comprises at least 110 contiguous nucleotides of SEQ ID NO:33.
14. The recombinant nucleic acid of claim 8 , wherein the nucleic acid comprises the nucleotide sequence of SEQ ID NO:33.
15. A recombinant host cell comprising a heterologous nucleic acid comprising a nucleotide sequence that encodes at least 12 contiguous amino acids of SEQ ID NO:34 or SEQ ID NO:59, said nucleic acid sequence operably linked to a heterologous promoter.
16. The recombinant host cell of claim 15 , further defined as an E. coli cell.
17. The recombinant host cell of claim 15 , wherein the nucleotide sequence encodes at least 50 contiguous amino acids of SEQ ID NO:34 or SEQ ID NO:59.
18. The recombinant host cell of claim 15 , wherein the nucleotide sequence encodes a peptide comprising SEQ ID NO:34 or SEQ ID NO:59.
19. A method of assaying for Borrelia infection comprising:
(a) contacting a sample obtained from a subject with an isolated polypeptide comprising at least 12 contiguous amino acids of SEQ ID NO:59 or SEQ ID NO:34; and
(b) determining whether immunologic binding occurs between the isolated polypeptide and an antibody in the sample, wherein immunologic binding is indicative of Borrelia infection.
20. The method of claim 19 , wherein the isolated polypeptide sequence comprises at least 35 contiguous amino acids of SEQ ID NO:59 or SEQ ID NO:34.
21. The method of claim 19 , wherein the isolated polypeptide sequence comprises at least 50 contiguous amino acids of SEQ ID NO:59 or SEQ ID NO:34.
22. The method of claim 19 , wherein the isolated polypeptide sequence comprises the sequence of SEQ ID NO:59 or SEQ ID NO:34.
23. The method of claim 19 , wherein the isolated polypeptide comprises a label.
24. The method of claim 19 , wherein the isolated polypeptide is a fusion protein.
25. The method of claim 19 , further defined as comprising performing an ELISA assay.